Jim Simons Akari Therapeutics PLC Transaction History

Renaissance Technologies LLC

  • $56.7 Billion
  • Q2 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$0.16 - $0.22 $5,552 - $7,634
34,700 Added 12.24%
318,250 $54,000
Q1 2023

May 12, 2023
BUY
$0.15 - $0.54 $34,215 - $123,174
228,100 Added 411.36%
283,550 $52,000
Q4 2022

Feb 13, 2023
BUY
$0.41 - $12.8 $6,314 - $197,120
15,400 Added 38.45%
55,450 $26,000
Q3 2022

Nov 14, 2022
SELL
$0.6 - $12.6 $3,540 - $74,340
-5,900 Reduced 12.84%
40,050 $25,000
Q2 2022

Aug 12, 2022
SELL
$0.95 - $1.22 $285 - $366
-300 Reduced 0.65%
45,950 $46,000
Q1 2022

May 13, 2022
SELL
$1.09 - $1.53 $15,302 - $21,479
-14,039 Reduced 23.29%
46,250 $56,000
Q4 2021

Feb 11, 2022
SELL
$1.38 - $1.74 $6,984 - $8,806
-5,061 Reduced 7.74%
60,289 $90,000
Q3 2021

Nov 12, 2021
SELL
$1.59 - $1.87 $136,813 - $160,906
-86,046 Reduced 56.84%
65,350 $107,000
Q2 2021

Aug 13, 2021
BUY
$1.69 - $2.85 $31,510 - $53,138
18,645 Added 14.05%
151,396 $262,000
Q1 2021

May 13, 2021
BUY
$1.81 - $3.88 $45,429 - $97,384
25,099 Added 23.31%
132,751 $350,000
Q4 2020

Feb 10, 2021
SELL
$1.5 - $2.02 $1,491 - $2,007
-994 Reduced 0.91%
107,652 $199,000
Q3 2020

Nov 13, 2020
SELL
$1.58 - $2.37 $39,500 - $59,250
-25,000 Reduced 18.71%
108,646 $189,000
Q2 2020

Aug 13, 2020
BUY
$1.16 - $2.61 $4,872 - $10,962
4,200 Added 3.24%
133,646 $291,000
Q1 2020

May 14, 2020
SELL
$1.06 - $2.16 $45,034 - $91,767
-42,485 Reduced 24.71%
129,446 $188,000
Q4 2019

Feb 13, 2020
BUY
$1.69 - $2.16 $61,348 - $78,410
36,301 Added 26.76%
171,931 $301,000
Q3 2019

Nov 13, 2019
BUY
$1.69 - $2.92 $1,064 - $1,839
630 Added 0.47%
135,630 $232,000
Q2 2019

Aug 12, 2019
BUY
$1.89 - $4.01 $219,240 - $465,160
116,000 Added 610.53%
135,000 $273,000
Q1 2019

May 14, 2019
BUY
$1.66 - $5.9 $31,540 - $112,100
19,000 New
19,000 $68,000

About Akari Therapeutics Plc

AKTX Quotes by TradingView
  • Ticker AKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,349,200
  • Market Cap $164M
  • Description
  • Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-...
More about AKTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email